RxDoctor Payments Data

Timothy Grossman, MD

Urology · Helena, MTNPI 1770584757

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $2,131 of the $3,502 with a category attached, or 60.9%. Angiodynamics, Inc. accounts for 64.8% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2022 at $1,387 and has fallen 65.5% since, to $478 in 2025.

$3,502in general payments, 2019–2025

Across 27 payments — averaging $129.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Angiodynamics, Inc.$2K
  • EDAP Technomed Inc$993
  • Axonics, Inc.$65
  • Teleflex LLC$46
  • Progenics Pharmaceuticals, Inc.$40
  • Astellas Pharma US Inc$38
  • plus $52 from 4 others

What the payments were for

  • Travel & lodging$1,36739%
  • Food & beverage$2,13161%
  • Education$40%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,502 in reported general payments places this provider in the 70th percentile of 45 urology providers in Montana.

See all urology providers in Montana

Medicare billing

Part B allowed, 2024
$219,776
Medicare patients
919
Services billed
2,515

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron256$139,844
GemtesaVibegron73$41,743
Tamsulosin Hcl1,186$18,506
Potassium Citrate ErPotassium Citrate193$12,659
Finasteride771$8,606
Alfuzosin Hcl ErAlfuzosin Hcl311$4,279
Methenamine Hippurate70$3,613
Trospium Chloride59$3,551
Oxybutynin Chloride158$2,436
Dutasteride73$1,637
Potassium Chloride52$1,629
Chlorthalidone89$1,546
Testosterone15$1,288
Bicalutamide45$1,213
NitrofurantoinNitrofurantoin Macrocrystal68$761

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$38$139,844256 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 45 urology providers in Montana.

Other urology in Helena

See the full list for Montana

Where these figures come from

Is this you, or does something look wrong? →